ÂÜÀòÂÒÂ×

Jay Venkatesan is the President, CEO and Director at Angion. Prior to joining Angion, Jay was the Executive Vice President & General Manager at Oncothyreon, Inc. from August 2014 to May 2015. Jay joined Oncothyreon following their acquisition of Alpine BioSciences to transition the operations and technology from Alpine. Prior to Alpine BioSciences, Jay co-founded Alpine Biosciences, Inc. in January 2014 and served as its CEO until the company was acquired by Oncothyreon in August 2014. From January 2008 to December 2013, Jay was a Managing Partner at Ayer Capital Management, LP. From July 2002 to December 2007, Jay served as a Director at Bain Capital (Brookside Capital). Prior to Bain Capital, Jay worked as an Investment Analyst at Apax Partners from June 1995 to August 1996 and as a Business Analyst at McKinsey & Company from August 1993 to June 1995.

Jay Venkatesan attended the University of Pennsylvania School of Medicine, where they earned their M.D. Jay also has a M.B.A. from The Wharton School, and a Bachelor of Arts in Chemistry from Williams College.

Some direct reports include Greg Curhan - CFO, Itzhak Goldberg - Executive Chairman & Chief Scientific Officer, and John F. Neylan - SVP & Chief Medical Officer.